

Canadian Society of Allergy and Clinical Immunology

Annual Scientific Virtual Meeting



October 22 to 24, 2020

PRELIMINARY PROGRAM

We are very pleased to host our 75th meeting of the Canadian Society of Allergy and Clinical Immunology. The CSACI Annual Scientific Meeting (ASM) is a highly anticipated event each year and is our Society's flagship event. It serves as a chance to network with colleagues, exchange ideas, and gain knowledge, while also socializing and renewing friendships. The health and safety of our members, our patients, staff, family and friends are our highest priority.


Due to the pandemic, the CSACI Board of Directors, along with the ASM Program and CPD Committees, have made the decision to convert the ASM planned for October to a **virtual platform**.

Our program will showcase both live streaming and recorded components. By converting to a virtual meeting, we will be able to reach those who could not have attended our in-person meeting in Ottawa. Our virtual meeting will provide our delegates with exceptional CPD, as well as the ability to share scientific news and best practices together...all without leaving home. It will feature a compelling array of sessions including Virtual talks, a Pro/Con debate and interactive workshops, as well as a virtual exhibit hall, which will reach audiences across Canada, the USA and beyond.

Have a great meeting!

Dr. Harold Kim
CSACI President

Dr. David Fischer
2020 Program Chair



2020 ANNUAL SCIENTIFIC MEETING PLANNING COMMITTEE

Dr. Harold Kim, CSACI President
Dr. David Fischer, 2020 ASM Chair, CPD Committee
Dr. Tim Vander Leek, CSACI Vice President
Dr. Anne Ellis, CSACI Treasurer, FIT Bowl Chair
Dr. Lori Connors, CPD Committee Chair, CSACI Board

Dr. Scott Cameron, 2020 Program Committee, CPD Com.
Dr. Edmond Chan, CSACI Board
Dr. Victoria Cook, 2020 Program Committee, CPD Com.
Dr. Keelia Farrell, FIT Representative
Dr. Charles Frankish, 2020 Program Committee, CPD Com.
Dr. Kyla Hildebrand, CSACI Board
Dr. Sandy Kapur, 2020 Program Committee
Dr. Elana Lavine, Pediatric Section Advisor
Dr. Doug Mack, CSACI Board
Dr. Christine McCusker, CSACI Board
Dr. Beata Derfalvi, Immunology Section Advisor
Dr. Andy O'Keefe, Asthma Section Advisor
Dr. Jackie Quirt, Rhino-sinusitis Section Advisor
Dr. Elinor Simons, Abstract Co-Chair
Dr. Julia Upton, Anaphylaxis and Food Allergy
Section Advisor
Dr. Hari Vliagoftis, CSACI Board and Abstract Co-Chair
Dr. Wade Watson, 2020 Program Committee, CPD Com.

Ms. Louise Tremblay, Executive Director
Ms. Alexi Campbell, Manager
Ms. Jasmin Lidington, Associate Executive Director

PROGRAM OBJECTIVES

The CSACI Annual Scientific Meeting's main objective is to provide current information about the diagnosis, treatment and management for conditions related to allergy, asthma and immunology. This meeting is a setting for interdisciplinary exchange among professionals and provides an excellent opportunity for participants to interact virtually with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, techniques, therapies and diagnostic procedures in allergy, asthma and immunology.

- Maintain competence on a wide variety of up-to-date topics in Clinical Immunology and Allergy
- Discuss hot new topics (both published and unpublished) that have arisen since the last CSACI meeting

- Establish a network of allergy and immunology colleagues from both community and university settings.
- Promote Clinical Immunology and Allergy as a specialty to our fellows-in-training, trainees and medical students.

WHY YOU SHOULD ATTEND!

As the premier meeting of the allergy, asthma and immunology community, this conference provides several unique and engaging educational opportunities for the participant – you can:

- Interact virtually with an impressive faculty of Canadian and international speakers;
- Network virtually with colleagues across settings and disciplines;
- Translate scientific discoveries into your practice;
- Learn about policy issues that directly affect you;
- Raise questions, debate the issues, plan follow-up studies, and discuss results;
- Discuss your own research and observations;
- Meet virtually with poster presenters to learn about their research objectives; and
- Visit the exhibit hall featuring products and services specifically designed for professionals in allergy, asthma and immunology.

TARGET AUDIENCE

The CSACI Annual Scientific meeting is intended for clinicians, researchers, trainees/students, and allied health professionals involved in research, treatment and management of diseases in allergy, asthma and immunology.

EVALUATIONS

Delegates can provide feedback on Annual Meeting Sessions they attend by using the Annual Meeting app or by visiting the CSACI website.

CSACI Mission:

The Canadian Society of Allergy & Clinical Immunology advances allergy, asthma, and immunology knowledge to optimize patient care across Canada.

CSACI Vision:

*The leading expertise for care of people with allergic and immunologic disease.
Striving for prevention and cure.*

ANNUAL GENERAL MEETING

All CSACI members are invited to attend the CSACI and CAAIF AGMs

DATE TO BE CONFIRMED – WILL BE HELD ON SEPARATE DATE AND TIME

Participants will be eligible to win a prize!

ACCREDITATION - (Section 1 & Section 3)

This event is an accredited group learning activity (Section 1 & Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please refer to the final program for accredited sessions.

AMA PRA Category 1 Credit™

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credits to AMA credits can be found at:

www.ama-assn.org/go/internationalcme.

CERTIFICATE OF ATTENDANCE

All participating delegates will receive an email containing their “Certificate of Attendance” following the meeting.

PROGRAM CHANGES AND CANCELLATIONS

Please note: The CSACI reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances.

DISCLOSURE

Faculty and Moderator Disclosure:

Current CME guidelines state that participants should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty and moderators have completed conflict of interest declarations and those potential conflicts will be listed in the announced at the beginning of each session.

The intent of this disclosure requirement is not to prevent a speaker with a conflict of interest from making a presentation but to make known the relationship, in advance, to the audience. It is intended that any conflict be openly identified so that with full disclosure of the facts, attendees may form their own judgments about the presentation.

In addition, all members of the annual scientific program committee have also completed their declaration and have announced at each teleconference or meeting any financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include, but is not limited to, being a direct shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to a sponsoring organization.

DISCLAIMER

The material presented at this meeting represents the opinion of the speakers and not the views of the CSACI. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the CSACI for reliance on any information presented during these educational activities. The CSACI does not guarantee, warrant or endorse any commercial products or services.

VISIT OUR 2020 SPONSORS AND EXHIBITORS IN THE EXHIBIT HALL

The CSACI meeting has proven to be a great opportunity for a collegial interchange of ideas and product information between physicians and our corporate partners. The exhibiting companies and organizations will provide you with the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology.



Want to win a gift card but
tired of filling out the
exhibitor passport?

The CSACI Trivia Game

...stay tuned for more details.

DON'T FORGET TO FOLLOW US ON TWITTER



Use **#CSACI20** when you tweet to participate in onsite conversations & share what you're learning with your colleagues



CSACI PROGRAM

THURSDAY, OCTOBER 22, 2020

1000-1200	NREP MEETING (CLOSED)
1010-1315	FIT SYMPOSIUM WORKSHOP, LUNCH AND ELECTIONS (CLOSED)
0930-1010	BREAKFAST AND ORIENTATION
1010-1045	SESSION 1: TRANSITION TO PRACTICE
1045-1115	BREAK
1115-1200	SESSION 2: ORAL FOOD CHALLENGES IN THE COMMUNITY
1200-1230	VIRTUAL LUNCH
1230-1250	ELECTIONS
1250-1315	SESSION 3: MAST CELL DISORDERS
1330-1600	IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY* *PLEASE NOTE THAT THIS SYMPOSIUM IS FREE OF CHARGE HOWEVER IF YOU WOULD LIKE TO ATTEND THE CSACI VIRTUAL CONFERENCE, YOU MUST PAY A REGISTRATION FEE AS PER YOUR STATUS.
1900-1915	OPENING REMARKS BY DR. HAROLD KIM AND DR. DAVID FISCHER
1915-2000	CO-DEVELOPED DINNER CO-SPONSORED: SANOFI GENZYME 1915-1945 SPEAKER: DR. TANYA LAIDLAW, BOSTON, MA TOPIC: ADVANCES IN THE TREATMENT OF NASAL POLYPOSIS OBJECTIVES: By the end of this session participants will be able to: <ol style="list-style-type: none">1. Define patient population that may benefit from treatment advances for nasal polyposis2. Compare and contrast current standard of care for nasal polyposis with biologics
1945-2000	DISCUSSION PERIOD

FRIDAY, OCTOBER 23, 2020

**PLEASE NOTE THAT FOOD COUPONS WILL BE SENT TO REGISTERED PARTICIPANTS
(PRIOR TO THE VIRTUAL MEETING)**

0900-0955

CO-DEVELOPED BREAKFAST

CO-SPONSORED: MEDEXUS

0925-0945 SPEAKER: DR. ZAINAB ABDURRHAMAN, TORONTO, ON

**TOPIC: AN APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF
GENERALIZED PRURITUS**

OBJECTIVES: By the end of this session participants will be able to:

- 1. Describe pathophysiology of pruritus**
- 2. Summarize appropriate diagnostic evaluation for pruritus**
- 3. Compose a treatment plan for a patient presenting with generalized pruritus (including CanMEDs Communicator role)**

0945-0955 DISCUSSION PERIOD

1000-1050

PLENARY SESSION I – FOOD ALLERGY

1000-1020 SPEAKER: DR. RUCHI GUPTA, CHICAGO, ILLINOIS

**TOPIC: DOES FOOD ALLERGY DISPROPORTIONATELY AFFECT PARTICULAR
RACES AND ETHNICITIES?**

OBJECTIVES: By the end of this session participants will be able to:

- 1. Summarize existing data on food allergy and race/ethnicity**
- 2. Consider conscious and unconscious bias in management of food allergy (CanMEDs advocacy role)**

1020-1040 SPEAKER: DR. SUSAN WASERMAN, HAMILTON, ON

**TOPIC: REVIEW OF NEW CANADIAN/WORLD ANAPHYLAXIS IN SCHOOLS
GUIDELINES**

OBJECTIVES: By the end of this session participants will be able to:

- 1. Compare Canadian and World anaphylaxis in schools' guidelines**
- 2. Explain implementation plan for Canadian anaphylaxis in schools' guidelines (CanMEDs advocacy role)**

1040-1050 DISCUSSION PERIOD

1050-1100

**VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE
PRESENTATION BY PHARMA)**

FRIDAY, OCTOBER 23, 2020

- 1100-1150** **PLENARY SESSION II – PRACTICAL MANAGEMENT OF IMMUNE DISEASES**
1100-1120 **SPEAKER: DR. HILARY LONGHURST, UK**
TOPIC: HAE GUIDELINES DIAGNOSIS AND MANAGEMENT WITH AND WITHOUT COVID-19
OBJECTIVES: By the end of this session participants will be able to:
1. Summarize current HAE guidelines for all types of HAE
2. Explain modifications in HAE management due to COVID-10
- 1120-1140** **SPEAKER: DR. ANNE PHAM-HUY, OTTAWA, ON**
TOPIC: TO VACCINATE OR NOT TO VACCINATE: WHAT IS ROLE FOR VACCINATION IN PRIMARY AND SECONDARY IMMUNE DEFICIENCIES
OBJECTIVES: By the end of this session participants will be able to:
1. Specify when vaccines are contraindicated in PID and SID
2. Describe when to vaccinate in PID and SID
- 1140-1150** **DISCUSSION PERIOD**
- 1150-1210** **CSACI AWARDS PRESENTATIONS AND OTHER CSACI NEWS**
- 1210-1300** **CO-DEVELOPED LUNCH**
CO-SPONSORED BY MERCK
1230-1250 **SPEAKER: DR. JACLYN SMITH, MANCHESTER, UK**
TOPIC: ADVANCES IN COUGH RESEARCH
OBJECTIVES: By the end of this session participants will be able to:
1. Define chronic cough
2. Explain current diagnostic approach to chronic cough
3. Compare current treatments and new treatment advances in chronic cough
- 1250-1300** **DISCUSSION PERIOD**
- 1300-1355** **KEYNOTE PRESENTATION – IMMUNOLOGY OF COVID-19**
1310-1325 **SPEAKER: DR. CATHERINE BIGGS, VANCOUVER, BC**
TOPIC: MULTI-INFLAMMATORY RESPONSE SYNDROME IN COVID-19
OBJECTIVES: By the end of this session participants will be able to:
1. Define multi-inflammatory response syndrome (MIRS)
2. Discuss current Canadian and worldwide data on MIRS
- 1325-1340** **SPEAKER: DR. SCOTT HALPERIN, HALIFAX, NS**
TOPIC: THE RACE FOR A COVID-19 VACCINE
OBJECTIVES: By the end of this session participants will be able to:
1. Summarize vaccine development approach in Canada
2. Explain COVID-19 vaccine development approach
- 1340-1355** **DISCUSSION PERIOD**

FRIDAY, OCTOBER 23, 2020

1355-1405 VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)

1405-1455 PLENARY SESSION III – Update in Peanut/Nut Allergies

1405-1425 SPEAKER: DR. HELEN BROUGH, LONDON, UK
TOPIC: WHAT WE'VE LEARNED FROM THE PRO-NUTS STUDY ABOUT INTRODUCTION OF MULTIPLE NUTS AND SEEDS VIA CHALLENGES
OBJECTIVES: By the end of this session participants will be able to:

1. Describe approach to multi-food oral challenges
2. Explain Pro-Nuts study results and implications on clinical care

1425-1445 SPEAKER: DR. GEORGE DU TOIT, HARROW, UK
TOPIC: HOW DO WE DEFINE TOLERANCE IN PEANUT INTRODUCTION AND OIT STUDIES AND THE ROLE OF LEAP-TRIO?
OBJECTIVES: By the end of this session participants will be able to:

1. Define tolerance in peanut introduction
2. Generalize study findings to clinical care of food allergic patients in Canada

1445-1455 DISCUSSION PERIOD

1455-1500 SPEAKER AWARDS PRESENTATION

1500-1640 PLENARY SESSION IV – SECTION 3 CONCURRENT SESSIONS (CHOOSE YOUR TIMES AND TOPICS)

1500-1530	ORAL IMMUNOTHERAPY PRACTICAL MANAGEMENT SPEAKERS: DR. VICTORIA COOK, DR. SCOTT CAMERON OBJECTIVES: By the end of this session participants will be able to: <ol style="list-style-type: none">1. Perform OIT in an outpatient clinic environment2. Manage side effects and reactions in OIT
1535-1605	
1610-1640	
1500-1530	SCIT/SLIT Challenging CASE SPEAKERS: DR. SAMIRA JEIMY, DR. BILL MOOTE OBJECTIVES: By the end of this session participants will be able to: <ol style="list-style-type: none">1. Manage complex SCIT/SLIT cases2. Obtain informed consent for SCIT/SLIT (CanMEDs Communicator role)
1535-1605	
1610-1640	

FRIDAY, OCTOBER 23, 2020

1500-1640

PLENARY SESSION IV – SECTION 3 CONCURRENT SESSIONS (CHOOSE YOUR TIMES AND TOPICS - **CONTINUED**)

1500-1530	MANAGING PSYCHOSOCIAL ASPECTS OF CARE IN ALLERGY/IMMUNOLOGY SPEAKERS: DR. LORI CONNORS, DR. WADE WATSON OBJECTIVES: By the end of this session participants will be able to: <ol style="list-style-type: none">1. Work in intra and inter-professional teams to manage complex allergy/immunology patients (CanMEDs Collaborator and Leader role)2. Discuss psychosocial aspects of care in allergy/immunology (CanMEDs Communicator role)
1535-1605	
1610-1640	

1500-1610

CONCURRENT TALK – BASIC SCIENCE - "NEURO-IMMUNE INTERACTIONS IN ALLERGY AND IMMUNOLOGY"

There is clear evidence that allergic inflammation involves constant cross-talk between immune cells and the nervous systems. Mediators, including cytokines, released by immune cells can modulate peripheral and central nervous system function, in turn altering neural control of inflammation and influencing the development and severity of allergic disease. In this session we will discuss some of these mechanisms.

OBJECTIVES: By the end of this session participants will be able to:

1. Explain cross-talk between immune cells and the nervous system
2. Discuss mechanisms of neuro-immune interactions in allergy and immunology

1500-1530 **SPEAKER: TBC**
TOPIC: TBC

1530-1540 **MINI BREAK AND VISIT VIRTUAL EXHIBIT**

1540-1610 **SPEAKER: TBC**
TOPIC: TBC

1640-1655

VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)

1700-1800

FIT BOWL

OBJECTIVES: By the end of this session participants will be able to:

1. Review interesting facts in allergy and immunology

SATURDAY, OCTOBER 24, 2020

- 0830-0900** **VIRTUAL YOGA SESSION**
- 0900-0955** **CO-DEVELOPED BREAKFAST AND
CO-SPONSORED BY ALK**
0925-0945 **SPEAKER: DR. ANNE ELLIS, KINGSTON, ON**
TOPIC: ADVANCES IN SLIT IN 2020
OBJECTIVES: By the end of this session participants will be able to:
1. Analyze data on safety and efficacy of SLIT
 2. Discuss therapeutic advances in SLIT
- 0945-0955** **DISCUSSION PERIOD**
- 1000-1050** **PLENARY SESSION V - ASTHMA PLENARY: GINA GUIDELINES**
- 1000-1020** **SPEAKER: DR. DIANNE LOUGHEED, KINGSTON, ON**
TOPIC: COMPARING CTS GUIDELINES TO GINA GUIDELINES
OBJECTIVES: By the end of this session participants will be able to:
1. Summarize CTA and GINA guidelines
 2. Compare and contrasts CTS guidelines with GINA guidelines
- 1020-1040** **SPEAKER: DR CONNIE YANG, Vancouver, BC**
TOPIC: PEDIATRIC IMPLICATIONS OF GINA GUIDELINES
OBJECTIVES: By the end of this session participants will be able to:
1. Explain implications on GINA guidelines on the pediatric population
 2. Discuss gaps in evidence that may impact implementation of GINA guidelines in pediatrics (CanMEDs Scholar role)
- 1040-1050** **DISCUSSION PERIOD**
- 1050-1100** **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE
PRESENTATION BY PHARMA)**

SATURDAY, OCTOBER 24, 2020

1100-1210

PLENARY SESSION VI – CONCURRENT SESSIONS

FOOD ALLERGY- OIT SESSIONS	IMMUNOLOGY SESSIONS
<p>1100-1120 SPEAKERS: DRS. EDMOND CHAN AND PHILIPPE BÉGIN, VANCOUVER, BC AND MONTREAL, QC TOPIC: NEW CANADIAN OIT GUIDELINES OBJECTIVES: By the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe Canadian OIT guidelines 2. Evaluate guidelines and whether you will incorporate them into your practice 	<p>1100-1120 SPEAKER: DR. TROY TORGERSON TOPIC: IMMUNE DYSREGULATION/ AUTOIMMUNITY IN INBORN ERRORS OF IMMUNITY OBJECTIVES: By the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Define immune dysregulation in inborn errors of immunity 2. Develop an approach to diagnosis and management of immune dysregulation
1120-1130 Discussion Period	1120-1130 Discussion Period
<p>1130-1150 SPEAKER: DR. HAROLD KIM, KITCHENER, ON TOPIC: WHAT IS THERE TO BE DONE ABOUT THE BILLING ISSUES IN OIT IN CANADA OBJECTIVES: By the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Compare and contrast current billing structures for OIT across Canada 2. Advocate for improved access to OIT for patients (CanMEDs advocacy role) 	<p>1130-1150 SPEAKER: DR. STUART TURVEY, VANCOUVER, BC TOPIC: GERMLINE CBM-OPATHIES: FROM IMMUNODEFICIENCY TO ATOPY OBJECTIVES: By the end of this session participants will be able to:</p> <ol style="list-style-type: none"> 1. Define germline CBM-opathies 2. Summarize clinical phenotypes of germline CBM-opathies
1150-1210 DISCUSSION PERIOD	1150-1210 DISCUSSION PERIOD

1210-1255

CO-DEVELOPED LUNCH

CO-SPONSORED BY GLAXOSMITHKLINE

1230-1250 SPEAKER: Dr. Richard Leigh, Calgary, AB

TOPIC: BIOLOGICS GINA-ASTHMA

OBJECTIVES: By the end of this session participants will be able to:

1. Classify asthma by phenotype
2. Describe classes of biologics for asthma
3. Discuss GINA guidelines as they pertain to biologics in asthma

1250-1300 DISCUSSION PERIOD

SATURDAY, OCTOBER 24, 2020

- 1300-1330** **PRO-CON DEBATE**
SPEAKERS:
PRO: DR CHARLES CHAN, TORONTO, ON
CON: DR. MEYER BALTER, TORONTO, ON
TOPIC: BIRT: BUDESONIDE/FORMOTEROL AS NEEDED IS A BETTER THERAPEUTIC APPROACH TO MILD ASTHMA THAN REGULAR USE OF INHALED CORTICOSTEROIDS
OBJECTIVES: By the end of this session participants will be able to:
1. Compare and contrast data on budesonide/formoterol as needed and regular use of inhaled corticosteroids
- 1330-1340** **DISCUSSION PERIOD**
- 1340-1350** **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**
- 1350-1500** **ORAL ABSTRACT QUICK SNAPPERS + VIEWING TIME FOR VIRTUAL POSTERS**
- 1500-1510** **VISIT VIRTUAL EXHIBIT HALL - SPONSORED BREAK (INCLUDES TWO-MINUTE PRESENTATION BY PHARMA)**
- 1510-1530** **PLENARY SESSION VII – ANAPHYLAXIS**
MODERATOR: DR. ANNE ELLIS, KINGSTON
1510-1530 SPEAKER: DR. WALEED ALQURASHI, OTTAWA
TOPIC: CANADIAN ADVANCES IN ANAPHYLAXIS MANAGEMENT: TREKK IMPLEMENTATION AND NEW RECOMMENDATIONS ON STEROIDS
OBJECTIVES: By the end of this session participants will be able to:
1. Define TREKK
2. Synthesize data on advances in anaphylaxis management
- 1530-1540 DISCUSSION PERIOD**
- 1540-1600** **CLOSING REMARKS BY DR. HAROLD KIM AND BY DR. TIM VANDER LEEK, NEW CSACI PRESIDENT**